Olanzapine Matches Dexmedetomidine for Delirium, Signals Lower Mortality
This single-center randomized trial directly compares oral olanzapine against low-dose intravenous dexmedetomidine for treating established ICU delirium, an area where efficacy data are scarce and guidelines remain noncommittal.
olanzapinedexmedetomidineantipsychoticsalpha-2 agonistsICU deliriumsedationcritical carerandomized controlled trialmortalityCAM-ICUCritical Care / ICU
Background Information
Olanzapine and dexmedetomidine offer dual options for ICU delirium management.
Managing delirium in critically ill patients can significantly affect outcomes, including length of ICU stay and overall recovery. The study found olanzapine and low-dose dexmedetomidine both effective for delirium, but with different side effect profiles. This study informs clinicians on alternative pharmacological strategies for ICU delirium, noting the potential side effects and efficacy of each option. Olanzapine and dexmedetomidine are effective for ICU delirium with varying side effect considerations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.